Get the Stockscreener App
37.06
5.76%
2.02
After Hours:
37.06
Maplight Therapeutics Inc stock is traded at $37.06, with a volume of 588.34K.
It is up +5.76% in the last 24 hours and up +32.31% over the past month.
MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.
See More
Previous Close:
$35.04
Open:
$35.05
24h Volume:
588.34K
Relative Volume:
1.64
Market Cap:
$1.68B
Revenue:
-
Net Income/Loss:
$-161.15M
P/E Ratio:
-9.976
EPS:
-3.7149
Net Cash Flow:
$-138.61M
1W Performance:
+3.40%
1M Performance:
+32.31%
6M Performance:
+130.76%
1Y Performance:
+0.00%
1-Day Range:
$34.31
$37.27
1-Week Range:
$33.92
$37.61
52-Week Range:
$12.24
$37.61
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
650-839-4360
Address
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
37.06 | 1.59B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-26 | Initiated | Needham | Buy |
| Apr-07-26 | Initiated | TD Cowen | Buy |
| Mar-19-26 | Initiated | Canaccord Genuity | Buy |
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
View All
Maplight Therapeutics Inc Stock (MPLT) Latest News
MPLTMapLight Therapeutics Inc Options - Finviz
MapLight Therapeutics autism drug shows mixed potential in adolescents - MSN
Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout - TipRanks
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout? - Yahoo Finance
Number of shareholders of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to book forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to earnings forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Enterprise value to EBITDA forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to sales forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Raymond James Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $46 - Moomoo
Maplight Therapeutics (MPLT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
MPLT Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 MapLight Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
MapLight Therapeutics, Inc. Actuals & Estimates (NASDAQ:MPLT) - TradingView
Tonix, MapLight are new strong buys at Raymond James on upcoming catalysts - MSN
MapLight Therapeutics: The Cobenfy Challenger Does Not Look Like A Bargain (NASDAQ:MPLT) - Seeking Alpha
Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts - Seeking Alpha
MPLT Initiated Coverage On by Raymond James -- Strong Buy Rating - GuruFocus
MapLight Therapeutics Initiated at Strong Buy by Raymond James - Moomoo
Raymond James initiates MapLight stock with strong buy on drug trial - Investing.com Canada
MapLight Therapeutics, Inc. 2026 Annual Meeting Results and Company Information – SEC 8-K Filing Summary - Minichart
MapLight Therapeutics appoints two directors to board - Investing.com
MapLight Therapeutics appoints two directors to board By Investing.com - Investing.com India
MapLight Shareholders Back Board Slate and Auditor - TipRanks
MapLight Therapeutics Announces Changes to Board of Directors - The Manila Times
MapLight Therapeutics Appointed Martin Babler, Troy Cox to Bd >MPLT - Moomoo
MPLT Maintained by Craig-Hallum -- Price Target Lowered to $40 - GuruFocus
Analyst Maintains Buy/Outperform on ML-004’s Safety, Irritability Signal and Pipeline Strength; Price Target Steady at $45 - TipRanks
Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained - TipRanks
MapLight Therapeutics stock maintained at Buy by H.C. Wainwright - Investing.com Australia
MPLT Maintained by Needham -- Price Target Raised to $42.00 - GuruFocus
Why is MapLight Therapeutics stock rallying today? - Investing.com
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents - Sahm
Form 144 MAPLIGHT THERAPEUTICS For: 10 February - Investing.com
MapLight reports Phase 2 autism trial results for ML-004 - grafa.com
Why is MapLight Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Form 8K MapLight Therapeutics Inc For: 22 June - Investing.com UK
MapLight Reports Phase 2 Data for Autism Candidate - TipRanks
MapLight’s autism drug trial misses primary endpoint By Investing.com - Investing.com Australia
H.C. Wainwright reiterates MapLight Therapeutics stock rating on muscarinic mechanism potential - Investing.com Canada
MapLight Therapeutics' Phase 2 Trial of ML-004 in Autism Spectrum Disorder Fails to Meet Primary Endpoint - Moomoo
MapLight’s autism drug trial misses primary endpoint - Investing.com
Form 8K MapLight Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Strong adolescent irritability signal in MapLight (MPLT) ML-004 Phase 2 IRIS trial - Stock Titan
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder - The Manila Times
MapLight Therapeutics, Inc.(NasdaqGS:MPLT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Maplight Therapeutics Inc Stock (MPLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Maplight Therapeutics Inc Stock (MPLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hanson Kristopher | General Counsel |
May 11 '26 |
Sale |
30.13 |
13,917 |
419,263 |
162,331 |
| Kroeger Christopher A. | Chief Executive Officer |
May 08 '26 |
Sale |
27.69 |
34,411 |
952,835 |
1,526,309 |
| Kroeger Christopher A. | Chief Executive Officer |
May 07 '26 |
Sale |
28.65 |
20,100 |
575,797 |
1,560,720 |
| Kroeger Christopher A. | Chief Executive Officer |
May 11 '26 |
Sale |
30.11 |
13,980 |
421,002 |
1,512,329 |
| Foff Erin Pennock | Chief Medical Officer |
May 07 '26 |
Sale |
28.54 |
4,438 |
126,640 |
346,059 |
| Lillie James Woodruff | Chief Scientific Officer |
May 07 '26 |
Sale |
28.28 |
721 |
20,390 |
242,729 |
| Setia Vishwas | Chief Financial Officer |
May 04 '26 |
Sale |
28.11 |
14,904 |
418,930 |
377,723 |
| Setia Vishwas | Chief Financial Officer |
May 05 '26 |
Sale |
28.20 |
10,903 |
307,444 |
366,820 |
| Setia Vishwas | Chief Financial Officer |
May 06 '26 |
Sale |
28.24 |
10,564 |
298,345 |
356,256 |
| Foff Erin Pennock | Chief Medical Officer |
May 06 '26 |
Sale |
28.76 |
24,052 |
691,749 |
350,497 |
1.17%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):